| Source: |
| Type: |
| Blood-Brain Barrier(BBB) is a term often used regarding if a product has the ability to cross the BBB. |
| 6061- | SeNPs, | MET, | Multifunctional mesoporous nanoselenium delivery of metformin breaks the vicious cycle of neuroinflammation and ROS, promotes microglia regulation and alleviates Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 6060- | SeNPs, | Multifunctional Selenium Quantum Dots for the Treatment of Alzheimer's Disease by Reducing Aβ-Neurotoxicity and Oxidative Stress and Alleviate Neuroinflammation |
| - | Study, | AD, | NA |
| 6059- | SeNPs, | Multifunctional Selenium Nanoparticles with Different Surface Modifications Ameliorate Neuroinflammation through the Gut Microbiota-NLRP3 Inflammasome-Brain Axis in APP/PS1 Mice |
| - | in-vivo, | AD, | NA |
| 6057- | SeNPs, | Dual-functional selenium nanoparticles bind to and inhibit amyloid β fiber formation in Alzheimer's disease |
| - | in-vitro, | AD, | PC12 |
| 6055- | SeNPs, | CUR, | RES, | Latest Perspectives on Alzheimer's Disease Treatment: The Role of Blood-Brain Barrier and Antioxidant-Based Drug Delivery Systems |
| - | NA, | AD, | NA |
| 6048- | SeNPs, | Unravelling the in vitro and in vivo potential of selenium nanoparticles in Alzheimer's disease: A bioanalytical review |
| - | Review, | AD, | NA |
| 6046- | SeNPs, | CGA, | Anti-amyloidogenic properties of 5‑caffeoylquinic acid-capped selenium nanoparticles |
| - | Study, | AD, | NA |
| 4469- | SeNPs, | Selenium Nanoparticles in Cancer Therapy: Unveiling Cytotoxic Mechanisms and Therapeutic Potential |
| - | Review, | Var, | NA |
| 4199- | SFN, | Sulforaphane and Brain Health: From Pathways of Action to Effects on Specific Disorders |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3663- | SFN, | Efficacy of Sulforaphane in Neurodegenerative Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3661- | SFN, | Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression |
| - | in-vitro, | AD, | NA |
| 3319- | SIL, | Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3646- | SIL, | "Silymarin", a promising pharmacological agent for treatment of diseases |
| - | Review, | NA, | NA |
| 3951- | Taur, | Taurine Supplementation Alleviates Blood Pressure via Gut–Brain Communication in Spontaneously Hypertensive Rats |
| - | in-vivo, | NA, | NA |
| 3561- | TQ, | Studi In Silico Potensi Piperine, Piperlongumine, dan Thymoquinone Sebagai Obat Alzheimer |
| - | NA, | AD, | NA |
| 3570- | TQ, | Thymoquinone alleviates the experimentally induced Alzheimer's disease inflammation by modulation of TLRs signaling |
| - | in-vivo, | AD, | NA |
| 4869- | Uro, | Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4864- | Uro, | Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4861- | Uro, | Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions |
| - | in-vivo, | AD, | NA |
| 4876- | Uro, | Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 4880- | Uro, | Urolithins: A Prospective Alternative against Brain Aging |
| - | Review, | AD, | NA |
| 4033- | VitB3, | Can nicotinamide riboside protect against cognitive impairment? |
| - | in-vivo, | AD, | NA |
| 4329- | VitB5, | Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer's Disease Pathogenesis in a Transgenic Mouse Model |
| - | in-vivo, | AD, | NA |
| 4328- | VitB5, | Pantethine |
| - | Review, | AD, | NA |
| 3129- | VitC, | Therapeutic treatment with vitamin C reduces focal cerebral ischemia-induced brain infarction in rats by attenuating disruptions of blood brain barrier and cerebral neuronal apoptosis |
| - | in-vivo, | Stroke, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1123 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid